Positron Corporation Transitions to SEC Reporting Status
Buffalo, NY – Positron Corporation (“Positron” or the “Company”) (OTC: POSC), known for its advancements in molecular imaging technology and services, has officially become a reporting company with the U.S. Securities and Exchange Commission (SEC). This decision marks a significant step in the Company’s commitment to transparency and regulatory compliance.
Significance of Becoming an SEC Reporting Company
This transition is a pivotal moment for Positron, reflecting its growth and maturity in the market. By submitting a Form 10 registration statement, Positron has disclosed all necessary financial statements, thus now adhering to the reporting requirements outlined in the Securities Exchange Act of 1934. This compliance will provide stakeholders with timely insights through quarterly and annual reports, ensuring they are informed about material events affecting the Company.
CEO Statement on the Transition
Adel Abdullah, the CEO of Positron Corporation, expressed enthusiasm about this achievement. He stated, "This transformation underscores our dedication to fostering transparency while building a world-class organization in molecular imaging. With the roll-out of our innovative 4D PET-CT system, our SEC reporting status will reinforce the confidence of our investors, customers, and partners in our operations and accountability standards."
Market Demand and Growth Opportunities
As the demand for PET-CT imaging, especially in cardiology and oncology, continues to surge, Positron is well-positioned to capitalize on these emerging opportunities. The Company boasts an expanding range of products and services, including a unique partnership with Neusoft Medical Systems in North America. This collaboration not only strengthens their market position but also enhances their ability to deliver cutting-edge solutions to healthcare providers.
Capital Market Access
Mr. Abdullah further added, "Achieving SEC reporting status will allow us greater access to capital markets, which is essential for driving Positron’s long-term growth strategies. We are enthusiastic about delivering high-performance, affordable molecular imaging solutions to medical practices and hospitals, both nationally and globally."
About Positron Corporation
Positron Corporation is a specialized medical technology company dedicated to the development, manufacturing, and marketing of state-of-the-art PET and PET-CT imaging systems. These systems are instrumental for healthcare providers in North America as they provide significant advantages in diagnosing cardiovascular diseases and enhancing patient care.
Innovative Solutions in Cardiac Imaging
Focused on the domain of cardiac Positron Emission Tomography (PET), Positron stands out in delivering superior imaging technologies. Their PET/PET-CT solutions are integral for tackling coronary artery disease, offering accurate diagnoses that lead to improved patient outcomes while prioritizing cost-effectiveness.
Commitment to Advancing Technology
Positron’s commitment to enhancing both the cardiac and oncology PET modalities drives their innovation. Their strong partnership with Shenyang Intelligent Neuclear Technology Co., a subsidiary of Neusoft Medical Systems, empowers Positron to expand their technological capabilities and bring unmatched value to imaging specialists.
Frequently Asked Questions
What is the significance of Positron becoming an SEC reporting company?
This change enhances the Company’s financial transparency and opens new avenues for growth and capital market access.
What technologies does Positron focus on?
Positron specializes in state-of-the-art PET and PET-CT imaging systems for nuclear medicine providers.
How does SEC reporting benefit investors?
It provides investors with consistent financial updates and reassures them about the Company’s accountability and transparency.
What is Positron's market position?
Positron is strategically positioned to capture significant market share in the PET-CT and nuclear imaging sectors.
What are Positron's long-term objectives?
The Company aims to expand its market presence and enhance technology offerings in molecular imaging.
